Novartis Pharmaceuticals

Fullerton, California

OncologyFiled/ApprovedListed · NVS

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

What changed

Phase I trial registered: Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation

1w agoTrial registeredJul 10, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
Study registered
Jul 15, 2026
Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease · NOT_YET_RECRUITING · sponsor: Novartis Pharmaceuticals · A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
ClinicalTrials.gov · NCT07683065 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jun 9, 2026
Inclisiran Formulation · RECRUITING · sponsor: Novartis Pharmaceuticals · Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
ClinicalTrials.gov · NCT07626281 (opens the source filing in a new tab)
Trial
Study registered
Apr 17, 2026
Leukemia, Chronic Myeloid · RECRUITING · sponsor: Novartis Pharmaceuticals · A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
ClinicalTrials.gov · NCT07549516 (opens the source filing in a new tab)
Trial
Study registered
Dec 22, 2025
Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis · RECRUITING · sponsor: Novartis Pharmaceuticals · Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
ClinicalTrials.gov · NCT07243782 (opens the source filing in a new tab)
Trial
Study registered
Dec 17, 2025
Chronic Myelogenous Leukemia - Chronic Phase · RECRUITING · sponsor: Novartis Pharmaceuticals · A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
ClinicalTrials.gov · NCT07091019 (opens the source filing in a new tab)
Trial
PHASE3 registered
Nov 27, 2025
Primary Immunoglobulin A Nephropathy (IgAN) · RECRUITING · sponsor: Novartis Pharmaceuticals · Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
ClinicalTrials.gov · NCT06994845 (opens the source filing in a new tab)
Trial
PHASE4 registered
Sep 9, 2025
Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease · RECRUITING · sponsor: Novartis Pharmaceuticals · Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
ClinicalTrials.gov · NCT06824103 (opens the source filing in a new tab)
Trial
PHASE3 registered
May 19, 2025
Lupus Nephritis · RECRUITING · sponsor: Novartis Pharmaceuticals · Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
ClinicalTrials.gov · NCT06711887 (opens the source filing in a new tab)
Trial
Study registered
May 1, 2025
Sepsis-associated Acute Kidney Injury · COMPLETED · sponsor: Novartis Pharmaceuticals · Concept Elicitation and Patient Experience Mapping in SA-AKI
ClinicalTrials.gov · NCT07180238 (opens the source filing in a new tab)
Trial
Study registered
Apr 30, 2025
Juvenile Idiopathic Arthritis · NOT_YET_RECRUITING · sponsor: Novartis Pharmaceuticals · Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis
ClinicalTrials.gov · NCT06431750 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 16, 2024
Sickle Cell Disease · ACTIVE_NOT_RECRUITING · sponsor: Novartis Pharmaceuticals · Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
ClinicalTrials.gov · NCT06155500 (opens the source filing in a new tab)
Trial
PHASE3 registered
Oct 27, 2023
Sjogrens Syndrome · ACTIVE_NOT_RECRUITING · sponsor: Novartis Pharmaceuticals · A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
ClinicalTrials.gov · NCT05985915 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jul 6, 2023
IgA Nephropathy, Immunoglobulin A Nephropathy · ACTIVE_NOT_RECRUITING · sponsor: Novartis Pharmaceuticals · A Study of Zigakibart in Adults With IgA Nephropathy
ClinicalTrials.gov · NCT05852938 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 13, 2023
Treatment-Resistant Depression · COMPLETED · sponsor: Novartis Pharmaceuticals · Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
ClinicalTrials.gov · NCT05454410 (opens the source filing in a new tab)
Trial
PHASE3 registered
Aug 22, 2022
Lupus Nephritis · TERMINATED · sponsor: Novartis Pharmaceuticals · Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
ClinicalTrials.gov · NCT05232864 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jul 14, 2022
Lupus Nephritis · ACTIVE_NOT_RECRUITING · sponsor: Novartis Pharmaceuticals · Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
ClinicalTrials.gov · NCT05126277 (opens the source filing in a new tab)
Trial
Study registered
Apr 13, 2022
Neovascular Age-related Macular Degeneration · TERMINATED · sponsor: Novartis Pharmaceuticals · Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting
ClinicalTrials.gov · NCT05266495 (opens the source filing in a new tab)
Trial
Study registered
Mar 9, 2021
Gastroenteropancreatic Neuroendocrine Tumor · COMPLETED · sponsor: Novartis Pharmaceuticals · Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
ClinicalTrials.gov · NCT04727723 (opens the source filing in a new tab)
Trial
Study registered
Jan 27, 2021
Allergic Rhinitis · COMPLETED · sponsor: Novartis Pharmaceuticals · Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies
ClinicalTrials.gov · NCT04648930 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jun 24, 2019
B-Cell Acute Lymphoblastic Leukemia · ACTIVE_NOT_RECRUITING · sponsor: Novartis Pharmaceuticals · Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
ClinicalTrials.gov · NCT03876769 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.95{"reasons":["name similarity 100%","semantic similarity 83%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.95{"reasons":["name similarity 100%","semantic similarity 82%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.94{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.92{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
new_entity links the trial record at 0.50{"reasons":["name similarity 100%"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
1w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
1w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
1w agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
3w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
4w agoTrial registeredSource (opens the source filing in a new tab)
Filed/Approved trial registered: Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
5w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
5w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
6w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
6w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
8w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
2mo agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Zigakibart in Adults With IgA Nephropathy
3mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies
4mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies
4mo agoTrial completedSource (opens the source filing in a new tab)
Study registered, no phase assigned: Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
4mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
4mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Concept Elicitation and Patient Experience Mapping in SA-AKI
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Concept Elicitation and Patient Experience Mapping in SA-AKI
7mo agoTrial completedSource (opens the source filing in a new tab)
Phase I trial registered: Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
9mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
May 2025Trial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
Apr 2025Trial completedSource (opens the source filing in a new tab)
Study registered, no phase assigned: Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis
Jan 2025Trial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting
Jan 2025Trial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

Study registered

PHASE1 registered

Study registered

Study registered

Study registered

PHASE3 registered

PHASE4 registered

PHASE3 registered

Study registered

Study registered

PHASE1 registered

PHASE3 registered

PHASE3 registered

PHASE2 registered

PHASE3 registered

PHASE3 registered

Study registered

Study registered

Study registered

PHASE2 registered